5 Best High Risk Penny Stocks to Buy Right Now

In this article, we will list the 5 Best High-Risk Penny Stocks to Buy Right Now. Please visit the 10 Best High Risk Penny Stocks to Buy Right Now if you’d like to see an extended list and how we came up with the list of the best high-risk penny stocks.

5. Equillium, Inc. (NASDAQ:EQ)

On March 13, Roth Capital analyst Adam Walsh initiated coverage of Equillium, Inc. (NASDAQ:EQ), assigning a Buy rating and a price target of $12. The firm’s assigned price target suggests a compelling 458% upside from the current levels. The firm noted that Equillium’s EQ504, an oral colon-targeted therapy, is entering Phase 1 trials for ulcerative colitis, using a mechanism that has already been validated. Despite this advancement, the analyst highlighted that the stock is currently trading as if it held an unproven asset, indicating a potential upside for investors who recognize the value of the drug’s clinical and scientific progress.

On the same day, Equillium, Inc. (NASDAQ:EQ) announced another development. The company entered into a definitive securities purchase agreement with RA Capital Management to raise approximately $35 million in gross proceeds. As part of the agreement, the company will issue around 18.9 million shares of its common stock, priced at $1.854 per share, or $1.8539 per pre-funded warrant sold instead of common stock at closing. The total gross proceeds are expected to reach $35 million before expenses, providing the company with additional capital to support its operations and ongoing development programs.

Equillium, Inc. (NASDAQ:EQ) operates as a clinical-stage biotechnology company. It develops therapies for severe autoimmune and inflammatory disorders in the United States, focusing on conditions with significant unmet medical needs. The company’s lead product candidate is Itolizumab (EQ001).